补肺益肾方治疗稳定期慢性阻塞性肺疾病患者临床疗效观察

Clinical observation of Bufei Yishen prescription in the treatment of patients with stable chronic obstructive pulmonary disease

目的 探讨补肺益肾方治疗稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者临床疗效。方法 选取我院诊治的稳定期COPD患者120例,随机分为对照组和治疗组,各60例。对照组采用西医常规综合治疗,治疗组在对照组的基础上联合中药补肺益肾方治疗,比较两组患者治疗后的中医证候积分、肺功能指标变化及不良反应情况。结果 治疗后,两组咳嗽、咳痰及喘息中医证候积分明显低于治疗前(P<0.05),且治疗组低于对照组(P<0.05)。治疗后,两组用力肺活量(forced vital capacity,FVC)占预计值的百分比、第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))预计值及FEV_(1)/FVC比值均明显高于治疗前(P<0.05),且治疗组高于对照组(P<0.05)。对照组不良反应总发生率为16.67%(10/60),治疗组不良反应总发生率为13.33%(8/60),两组不良反应发生率比较无显著差异(^(χ2)=1.872,P=0.609)。结论 补肺益肾方联合西药可改善稳定期COPD症状,安全有效。

Objective To explore the clinical efficacy of Bufei Yishen prescription in the treatment of patients with stable chronic obstructive pulmonary disease(COPD).Methods A total of 120 patients with stable COPD diagnosed and treated in our hospital were selected and randomly divided into the control group and the treatment group,60 cases in each.The control group received conventional comprehensive treatment of western medicine,and the treatment group was treated with traditional Chinese medicine Bufei Yishen prescription on the basis of the control group.The traditional Chinese medicine(TCM) syndrome scores,pulmonary function index changes and adverse reactions were compared between the two groups after treatment.Results After treatment,the TCM syndrome scores of cough,expectoration and wheezing in the two groups were significantly lower than those before treatment(P<0.05),and those in the treatment groups were lower than those in the control group(P<0.05).After treatment,the percentage of forced vital capacity(FVC) in the predicted value,the predicted value of forced expiratory volume in the first second(FEV_(1)),and the value of FEV_(1)/FVC in the two groups were significantly higher than those before treatment(P<0.05),and those in the treatment groups were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the control group was 16.67%(10/60),and 13.33%(8/60) in the treatment group,and there was no significant difference in the incidence of adverse reactions between the two groups(^(χ2)=1.872,P=0.609).Conclusion Bufei Yishen prescription combined with western medicine on stable COPD can improve the symptoms of patients,which is safe and effective,suitable for clinical application.